ISRG Intuitive Surgical Stock Outlook 2026: The da Vinci 5 Upgrade Cycle and Robotic Surgery's Next Decade
Intuitive Surgical stock analysis for 2026: da Vinci 5 FDA clearance and upgrade cycle implications, razor-and-blade model economics, Ion lung biopsy platform growth, competitive threats from Medtronic Hugo and J&J Ottava, and valuation framework for growth investors.
ISRG Intuitive Surgical da Vinci